Literature DB >> 7060325

Amiodarone kinetics after oral doses.

R Kannan, K Nademanee, J A Hendrickson, H J Rostami, B N Singh.   

Abstract

Amiodarone serum kinetics after single oral doses and after long-term therapy were investigated in patients with ventricular tachyarrhythmias. When amiodarone was given as a single oral dose (1400 to 1800 mg, n = 6), serum levels of amiodarone and its metabolite, measured by high-performance liquid chromatography, correlated (r = 0.69, P less than 0.01). Peak concentrations (amiodarone, 3 to 14 microgram/ml; metabolite, 0.7 microgram/ml) were attained in 4.9 +/- 1.2 hr. Using computer fits to the data, amiodarone mean elimination rate constant and half-life (t 1/2 e) were 0.128 +/- 0.063 hr-1 and 7.2 +/- 5.0 hr. In 12 patients given a mean dose of 1327 +/- 338 mg/day of amiodarone for 4.1 +/- 2.3 wk, mean serum amiodarone level was 3.84 +/- 2.92 microgram/ml (range 0.92 to 11.99); in three patients simultaneous determination of concentrations of amiodarone and its metabolite revealed that concentration of the latter was about 50% of that of the parent drug during long-term therapy. In four patients on maintenance therapy (400 to 800 mg/day, serum level 1.08 +/- 1.3 microgram/ml) drug was discontinued and serum amiodarone levels were determined serially. Serum drug disappearance followed a single exponential function with an elimination rate constant of 0.030 +/- 0.012 day-1 and t 1/2 e of 29 +/- 19 days. Our kinetic data are consistent with the long therapeutic amiodarone t 1/2 noted in the treatment of cardiac arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060325     DOI: 10.1038/clpt.1982.57

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  In vitro amiodarone protein binding and its interaction with warfarin.

Authors:  P Neyroz; M Bonati
Journal:  Experientia       Date:  1985-03-15

2.  Bioavailability of drugs with long elimination half-lives.

Authors:  R Urso; L Aarons
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  The potentiation of acenocoumarol anticoagulant effect by amiodarone.

Authors:  M Arboix; M E Frati; J R Laporte
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

5.  Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites.

Authors:  M Stäubli; A Troendle; B Schmid; P Balmer; B Kohler; H Studer; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

8.  Amiodarone in a newborn with ventricular tachycardia and an intracardiac tumor: adjusting the dose according to an individualized dosing regimen.

Authors:  T Bouillon; H Schiffmann; D Bartmus; U Gundert-Remy
Journal:  Pediatr Cardiol       Date:  1996 Mar-Apr       Impact factor: 1.655

Review 9.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 10.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.